US Stock MarketDetailed Quotes
VKTX Viking Therapeutics
- 52.940
- -1.570-2.88%
Close Nov 29 13:00 ET
- 53.010
- +0.070+0.13%
Post 17:01 ET
5.90BMarket Cap-56319P/E (TTM)
54.540High52.800Low1.54MVolume54.100Open54.510Pre Close81.94MTurnover1.47%Turnover RatioLossP/E (Static)111.44MShares99.41052wk High6.47P/B5.55BFloat Cap14.02052wk Low--Dividend TTM104.78MShs Float99.410Historical High--Div YieldTTM3.19%Amplitude0.880Historical Low53.333Avg Price1Lot Size
Viking Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -11.72%-21.96M | -149.35%-28.51M | 75.11%-6.13M | -51.61%-73.38M | -61.45%-17.64M | -45.63%-19.66M | 14.93%-11.44M | -134.03%-24.64M | -1.70%-48.4M | 11.53%-10.93M |
| Net income from continuing operations | -10.68%-24.94M | -15.73%-22.25M | -40.06%-27.36M | -24.73%-85.9M | -25.80%-24.61M | -42.86%-22.53M | -10.29%-19.23M | -21.29%-19.53M | -25.24%-68.87M | -58.30%-19.56M |
| Operating gains losses | ---113K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 19.18%87K | 2.74%75K | 2.78%74K | 0.34%292K | 2.78%74K | -48.59%73K | --73K | -6.49%72K | -1.69%291K | -5.26%72K |
| Other non cash items | 175.00%33K | -37.21%27K | -7.50%37K | 31.00%131K | 80.00%36K | -76.92%12K | 258.33%43K | 150.00%40K | 244.83%100K | 66.67%20K |
| Change In working capital | -170.93%-1.03M | -259.62%-8.01M | 289.80%15.95M | -65.18%3.55M | -15.48%5.48M | 48,600.00%1.46M | 298.73%5.02M | -442.60%-8.4M | 448.10%10.19M | 385.46%6.48M |
| -Change in receivables | 447.56%1.35M | -134.33%-157K | 169.55%655K | -47.72%321K | -187.83%-101K | 62.91%246K | -127.57%-67K | 131.43%243K | -47.79%614K | -80.64%115K |
| -Change in prepaid assets | -298.69%-2.73M | -101.07%-79K | 177.41%1.75M | 304.73%6.41M | 95.95%-58K | 66.83%1.37M | 388.95%7.35M | -9,917.39%-2.26M | -340.23%-3.13M | -366.45%-1.43M |
| -Change in payables and accrued expense | 677.92%445K | -253.26%-7.69M | 316.31%13.64M | -121.98%-2.83M | -27.38%5.72M | 91.10%-77K | -162.58%-2.18M | -362.56%-6.3M | 522.75%12.89M | 418.94%7.88M |
| -Change in other current liabilities | -10.34%-96K | -2.27%-90K | -3.53%-88K | -83.60%-347K | -3.57%-87K | 22.32%-87K | -206.02%-88K | -11.84%-85K | 44.74%-189K | 2.33%-84K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -11.72%-21.96M | -149.35%-28.51M | 75.11%-6.13M | -51.61%-73.38M | -61.45%-17.64M | -45.63%-19.66M | 14.93%-11.44M | -134.03%-24.64M | -1.70%-48.4M | 11.53%-10.93M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 306.65%25.9M | 38.35%-126.06M | -21,018.65%-459.79M | -427.08%-179.09M | 392.19%35.73M | -146.61%-12.53M | -1,177.36%-204.48M | 35.76%2.2M | 44.24%54.75M | -73.51%7.26M |
| Net investment purchase and sale | 306.65%25.9M | 38.35%-126.06M | -21,018.65%-459.79M | -427.08%-179.09M | 392.19%35.73M | -146.61%-12.53M | -1,177.36%-204.48M | 35.76%2.2M | 44.24%54.75M | -73.51%7.26M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 306.65%25.9M | 38.35%-126.06M | -21,018.65%-459.79M | -427.08%-179.09M | 392.19%35.73M | -146.61%-12.53M | -1,177.36%-204.48M | 35.76%2.2M | 44.24%54.75M | -73.51%7.26M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,508.11%2.52M | -98.91%2.91M | 14,384.63%606.04M | 6,418.76%271.38M | -98.25%188K | -840.00%-74K | 16,897.36%267.08M | 183.58%4.18M | -39.49%4.16M | 22,770.21%10.75M |
| Net common stock issuance | 2,360.86%46.66M | -100.01%-25K | 1,613,935.14%597.12M | --0 | -2,717,190.00%-271.73M | 18,860.00%1.9M | 16,221.27%269.87M | 99.28%-37K | ---6.8M | ---10K |
| Proceeds from stock option exercised by employees | 252,300.00%2.52M | 12.05%2.93M | 9.96%4.36M | 698.11%6.77M | 25.33%188K | ---1K | 3,013.10%2.62M | 545.93%3.97M | -88.89%848K | 127.27%150K |
| Net other financing activities | -2,269.63%-46.66M | --0 | 1,687.06%4.56M | 2,517.29%264.61M | 2,461.31%271.73M | ---1.97M | ---5.41M | 151.10%255K | 1,442.63%10.11M | 55,936.84%10.61M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,508.11%2.52M | -98.91%2.91M | 14,384.63%606.04M | 6,418.76%271.38M | -98.25%188K | -840.00%-74K | 16,897.36%267.08M | 183.58%4.18M | -39.49%4.16M | 22,770.21%10.75M |
| Net cash flow | ||||||||||
| Beginning cash position | -36.83%43.92M | 965.13%195.58M | 51.55%55.52M | 38.91%36.63M | 26.45%37.19M | 328.44%69.52M | 47.44%18.36M | 38.91%36.63M | -9.43%26.37M | 161.08%29.41M |
| Current changes in cash | 120.02%6.46M | -396.46%-151.67M | 867.27%140.11M | 79.81%18.91M | 158.10%18.28M | -340.70%-32.27M | 1,195.85%51.16M | -31.21%-18.26M | 483.07%10.52M | -53.11%7.08M |
| Effect of exchange rate changes | 57.35%-29K | 200.00%3K | -433.33%-48K | 88.37%-30K | -64.54%50K | 69.51%-68K | 98.30%-3K | ---9K | ---258K | --141K |
| End cash Position | 35.40%50.35M | -36.83%43.92M | 965.13%195.58M | 51.55%55.52M | 51.55%55.52M | 26.45%37.19M | 328.44%69.52M | 47.44%18.36M | 38.91%36.63M | 38.91%36.63M |
| Free cash flow | -11.72%-21.96M | -149.35%-28.51M | 75.11%-6.13M | -51.61%-73.38M | -61.45%-17.64M | -45.63%-19.66M | 14.93%-11.44M | -134.03%-24.64M | -1.70%-48.4M | 11.53%-10.93M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
